FII-INSTITUTE
7.9.2021 23:55:11 CEST | Business Wire | Press release
Population projections stress the need for sustainable living on our planet and on others. FII Institute announces today an investment in Interstellar Lab, a space technology company designing closed loop biodomes for sustaining life on Earth, the moon, and Mars.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210907005919/en/
FII Institute is a global non-profit foundation with an investment arm and one agenda: Impact on Humanity. The $500,000 USD equity investment is a part of Interstellar Lab's latest $3M USD Seed Round and builds on FII Institute's commitment to catalyze globally relevant, real-world solutions in Artificial Intelligence and Robotics, Education, Healthcare and Sustainability. Through the investment, the Institute will fund the development of, and leverage, AI simulation-based designs to tackle Earth’s most pressing environmental issues, paving the way to solutions in waste management, zero-impact living and resource-conscious agriculture.
“Climate change is a real emergency for Earth, and we only have a small window to bring about positive change. We are developing a new framework for sustainable living on Earth and a testbed for future space missions,” Barbara Belvisi, Founder and CEO, Interstellar Lab said. “Working with investors like FII Institute advances Interstellar Lab’s mission to support human life sustainably on Earth, the moon and Mars by generating and recycling food, water and air.”
FII Institute CEO Richard Attias said, "Space sector growth is creating new opportunities for advanced research and solutions in sustainability. Inspired by the design challenge of human settlement on Mars, Interstellar Lab has forged an innovative approach to sustaining life in the absence of the abundance taken for granted here on Earth. We are very pleased to support the technologies that will help reduce the burden on our planet and prepare us for the future."
This marks the third FII Institute investment this year following announcements to back Lilium, an electric-powered aircraft reducing the carbon impact of regional travel, and Red Sea Farms, AgTech making it possible to grow food using saltwater. With an inclusive agenda built on three pillars – THINK, XCHANGE, ACT – FII Institute empowers the brightest minds to leverage scientific innovation for positive change, brings leading solutions to reality through investment, and calls for global collaboration in the service of humanity.
About FII Institute (Future Investment Initiative Institute)
FII Institute is a global non-profit foundation with an investment arm and one agenda: Impact on Humanity. Committed to Environmental, Social and Governance (ESG) principles, we foster the brightest minds and transform ideas into real-world solutions.
When decision makers, investors and an engaged generation of youth come together, energized and ready for change, we harness that energy into three pillars – THINK, XCHANGE, ACT – and invest in the innovations that make a difference to lives globally.
About Interstellar Lab
Interstellar Lab is developing and building closed-loop sustainable living systems on Earth and in space. The company focuses on creating space-grade food production systems and habitat modules. The aim is double: to provide solutions regarding the current climate crisis and the need of new food production systems on Earth, and to develop closed-loop life support systems for lunar missions in the context of NASA’s Artemis Program and in the future for Mars exploration.
*Source : AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005919/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom